DOCK2 has been discovered to be linked with a prognostic factor in various cancers such as acute myeloid leukemia, prostate cancer, colorectal cancer, and non-small-cell lung cancer (Du et al.; Yu et al., 2015; Bjerre et al., 2019; Hu et al., 2019). Here, DOCK2 is linked to non-small cell lung carcinoma.